Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Sorrento Therape is a biotechnology business based in the US. Sorrento Therape shares (SRNE) are listed on the NASDAQ and all prices are listed in US Dollars. Sorrento Therape employs 799 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Advanced traders
| Latest market close | $2.07 |
|---|---|
| 52-week range | $1.15 - $11.07 |
| 50-day moving average | $1.63 |
| 200-day moving average | $4.21 |
| Wall St. target price | $21.00 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-1.53 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $2.07 from 2022-06-24
| 1 week (2022-06-17) | 23.21% |
|---|---|
| 1 month (2022-05-23) | 31.01% |
| 3 months (2022-03-24) | -17.86% |
| 6 months (2021-12-22) | N/A |
| 1 year (2021-06-25) | -79.01% |
|---|---|
| 2 years (2020-06-26) | -64.74% |
| 3 years (2019-06-26) | 3.37 |
| 5 years (2017-06-26) | 2.1 |
| Revenue TTM | $57 million |
|---|---|
| Gross profit TTM | $-167,049,000 |
| Return on assets TTM | -32.96% |
| Return on equity TTM | -206.57% |
| Profit margin | 0% |
| Book value | $0.62 |
| Market capitalisation | $653.4 million |
TTM: trailing 12 months
We're not expecting Sorrento Therape to pay a dividend over the next 12 months.
Sorrento Therape's shares were split on a 1:25 basis on 31 July 2013. So if you had owned 25 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Sorrento Therape shares – just the quantity. However, indirectly, the new 2400% higher share price could have impacted the market appetite for Sorrento Therape shares which in turn could have impacted Sorrento Therape's share price.
Over the last 12 months, Sorrento Therape's shares have ranged in value from as little as $1.15 up to $11.07. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Sorrento Therape's is 2.4288. This would suggest that Sorrento Therape's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Sorrento Therapeutics, Inc. , a clinical stage and commercial biopharmaceutical company, develops therapies for cancer, autoimmune, inflammatory, viral, and neurodegenerative diseases. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutic by leveraging its proprietary G-MAB antibody library and targeted delivery modalities, which include chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy, and antibody drug conjugate, as well as bispecific antibody approach; and Sofusa, a drug delivery technology that deliver biologic directly into the lymphatic system. Its clinical programs in development include anti-CD38 CAR-T therapy for the treatment of multiple myeloma, as well as for amyloidosis and graft versus host disease. The company develops resiniferatoxin, a non-opioid-based TRPV1 agonist neurotoxin for late stage cancer and osteoarthritis knee pain treatment; and ZTlido, a lidocaine delivery system for the treatment of postherpetic neuralgia. It engages in the development of SEMDEXA, an injectable viscous gel formulation, which is Phase III trial for the treatment of sciatica, a pathology of low back pain; SP-103, an investigational non-aqueous lidocaine topical system undergoing clinical development in chronic low back pain condition; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation for the treatment of fibromyalgia.
Everything we know about the Intchains Group IPO, plus information on how to buy in.
Everything we know about the Biostage IPO, plus information on how to buy in.
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
Everything we know about the OptMed IPO, plus information on how to buy in.
Everything we know about the Lichen China IPO, plus information on how to buy in.
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
Everything we know about the Nano Labs IPO, plus information on how to buy in.
Everything we know about the Warrantee IPO, plus information on how to buy in.
Everything we know about the Treasure Global IPO, plus information on how to buy in.
Everything we know about the BIOLIFE4D IPO, plus information on how to buy in.
